CS
VRTX icon

Credit Suisse’s Vertex Pharmaceuticals VRTX Stock Holding History

Credit Suisse’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,000
Closed -$1.32M – 4359
2021
Q4 		$1.32M Buy
6,000
+4,100
+216% +$797K ﹤0.01% 3098
2021
Q3 		$345K Sell
1,900
-14,800
-89% -$2.89M ﹤0.01% 4032
2021
Q2 		$3.37M Sell
16,700
-5,200
-24% -$1.09M ﹤0.01% 2427
2021
Q1 		$4.71M Sell
21,900
-19,800
-47% -$4.35M ﹤0.01% 2114
2020
Q4 		$9.86M Hold
41,700
– – ﹤0.01% 1592
2020
Q3 		$11.3M Buy
41,700
+8,400
+25% +$2.32M 0.01% 1304
2020
Q2 		$9.67M Buy
33,300
+10,800
+48% +$2.93M 0.01% 1305
2020
Q1 		$5.35M Sell
22,500
-25,100
-53% -$5.76M ﹤0.01% 1512
2019
Q4 		$10.4M Buy
47,600
+700
+1% +$142K 0.01% 1383
2019
Q3 		$7.95M Buy
46,900
+7,600
+19% +$1.34M 0.01% 1444
2019
Q2 		$7.21M Buy
39,300
+8,700
+28% +$1.52M 0.01% 1510
2019
Q1 		$5.63M Buy
+30,600
New +$5.65M 0.01% 1635

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Credit Suisse's VRTX Position: Q1 2024 in Review

Credit Suisse reduced its Vertex Pharmaceuticals (VRTX) stake by 11% in Q1 2024, selling an estimated $18.2M and leaving 349,294 shares worth $146M. The position accounts for 0.14% of the portfolio, ranked #132.

Credit Suisse first reported a position in VRTX in Q2 2013 and has held it in 44 quarters since. The position peaked at $264M in Q1 2021. 1,494 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

  • Credit Suisse held 349,294 shares of Vertex Pharmaceuticals worth $146M as of Q1 2024.
  • Credit Suisse sold 43,031 Vertex Pharmaceuticals shares in Q1 2024, an estimated $18.2M.
  • Vertex Pharmaceuticals made up 0.14% of Credit Suisse's portfolio in Q1 2024, its #132 holding.
  • Credit Suisse first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 44 quarters since.
  • Credit Suisse's Vertex Pharmaceuticals position peaked at $264M in Q1 2021.
  • 1,494 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.